I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced ...

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all ...

Akero Therapeutics Inc. advanced stock charts by Barron's. View 1AKRO historical stock data and compare to other stocks, and exchanges.

Week 96 data presented during a late-breaking oral session at EASL 2025 demonstrated the potential of EFX 50mg to reverse cirrhosis in high-need MASH subgroups, including patients with cryptogenic ...

In the last 3 months, 6 analysts have offered 12-month price targets for Akero Therapeutics. The company has an average price target of $62.67 with a high of $83.00 and a low of $33.00.

Shares of Akero Therapeutics (AKRO 2.11%) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence.

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Akero Therapeutics (AKRO) to $90 from $96 and keeps an Overweight rating on the shares. The company’s Q4 report was ...

Akero Therapeutics has a 1-year low of $17.86 and a 1-year high of $58.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.